VPI 013
Alternative Names: OPC-14523Latest Information Update: 27 Jul 2009
Price :
$50 *
At a glance
- Originator Otsuka Pharmaceutical
- Class Antidementias; Antidepressants; Neuroprotectants; Piperazines; Quinolines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin uptake inhibitors; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Major depressive disorder; Neuropathic pain
Most Recent Events
- 27 Jul 2009 No development reported - Phase-II for Depression in USA (PO)
- 27 Jul 2009 No development reported - Preclinical for Neuropathic pain in USA (PO)
- 25 Oct 2006 Vela Pharmaceuticals has been acquired by Pharmos Corporation